Analysis of two topotecan treatment schedules in patients with recurrent ovarian cancer e

被引：5
作者：
Bruchim, Ilan [1 ,2 ]
Ben-Harim, Zipi [1 ,2 ]
Piura, Ettie [1 ,2 ]
Haran, Gabi [1 ,2 ]
Fishman, Ami [1 ,2 ]
机构：
[1] Meir Med Ctr, Div Gynecol Oncol, 59 Tschernihovsky St, IL-44821 Kefar Sava, Israel
[2] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel
来源：
JOURNAL OF CHEMOTHERAPY | 2016年 / 28卷 / 02期
关键词：
Epithelial ovarian cancer; Chemotherapy; Topotecan; EPITHELIAL OVARIAN; PHASE-II; OPEN-LABEL; CHEMOTHERAPY; CARBOPLATIN; MANAGEMENT; CARCINOMA; THERAPY;
D O I：
10.1080/1120009X.2015.1115195
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Two topotecan treatment schedules in patients with recurrent epithelial ovarian cancer were evaluated. Protocol A (21 days) was 1.5 mg/m(2)/day topotecan on days 1 through 5 of a 21-day cycle; Protocol B (weekly) 4 mg/m(2) on days 1, 8, and 15 of a 28-day cycle. Efficacy was determined by clinical exam, CT scan, and CA125 levels. Forty-three patients on Protocol A and 21 on Protocol B were evaluated. As second-line treatment, Protocol A response was 9/20 (45%). Response to Protocol B was 4/17 (23.5%; NS). As third line or more, the response on Protocols A and B together was only 3/27 (11%). High-grade haematological toxicity was reported in 12/43 (27.9%) on Protocol A and 1/21 (4.8%) on Protocol B (p = 0.04). There was no difference in progression-free-intervals between schedules in second-line treatment. The weekly protocol had lower severe haematological toxicity. Clinical response in third line or more was very low.
引用
收藏
页码：129 / 134
页数：6
相关论文
共 31 条
[31]   A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy [J].
Spannuth, Whitney A. ;
Leath, Charles A., III ;
Huh, Warner K. ;
Barnes, Mack N., III ;
Davidson, Susan A. ;
Kilgore, Larry C. ;
Partridge, Edward E. ;
Austin, J. Maxwell, Jr. ;
Alvarez, Ronald D. .
GYNECOLOGIC ONCOLOGY, 2007, 104 (03) :591-595
1234